Truist raised the firm’s price target on Incyte (INCY) to $93 from $79 and keeps a Hold rating on the shares. The recent Incyte performance was driven primarily by execution of base business, management change, and broader sentiment, the analyst tells investors in a research note. The firm adds however that in the context of the looming Jakafi patent cliff, the recent pipeline progress in solid tumors/ET and favorable launches Niktimvo/Opzelura are “necessary but not sufficient” to fully de-risk and bridge the cliff.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte price target raised to $84 from $81 at RBC Capital
- Incyte price target raised to $109 from $104 at BofA
- Incyte’s Strong Financial Performance and Strategic Catalysts Drive Buy Rating
- Incyte price target raised to $97 from $89 at Wells Fargo
- Incyte price target raised to $101 from $90 at Barclays